DermWire | Newest Articles Newest Articles en-us Sun, 30 Apr 2017 16:32:44 GMT Sun, 30 Apr 2017 16:32:44 GMT DermWire AAN 2017 Meeting: Racial and Regional Disparities Identified Endovascular Care Delivery Access to endovascular care is significantly impacted by factors such as race, region, and hospital, according to findings presented this week at the American Academy of Neurology (AAN) Annual Meeting in Boston. Investigators analyzed data from a large registry to determine use of endovascular therapy in ischemic stroke patients. Among more than 58,000 patients in Florida and Puerto Rico, 3.6 percent received thrombectomy. Compared to those patients not treated with endovascular therapy, patient… Fri, 28 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 OPERA studies, ocrelizumab reduced the relapse rate by 55 percent compared to interferon beta-1a. Additional analyses of the OPERA studies showed the efficacy of ocrelizumab in people with early relapsing MS, suppressing more than 90 percent of active MRI lesions over two years compared with interferon beta-1… Wed, 26 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. When researchers analyzed the results from preliminary research for the two different types of vagotomy surgery, they found that people who had a truncal vagotomy at least five years earlier were less likely to develop Parkinson’s disease than those who had … Wed, 26 Apr 2017 04:00:00 GMT AAN Unveils New Guideline for SUDEP at Annual Meeting The American Academy of Neurology (AAN) and the American Epilepsy Society (AES) have released a new joint guideline for sudden unexpected death in epilepsy (SUDEP) at the AAN Annual Meeting in Boston. SUDEP is rare in children, affecting just one in 4,500 children every year, while in adults it affects one in 1,000 individuals every year, according to the new study. Based on a review of all available evidence showing, investigators found that general tonic-clonic seizures represent a major risk … Tue, 25 Apr 2017 04:00:00 GMT Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting in Los Angeles, the company reports. "Stereotactic Radiosurgery for Intractable Tremor-Dominant Parkinson Disease" reports a study that analyzed the outcomes of 33 patients who received Gamma Knife radiosurgery to treat medically refractory Parkinson's disease (PD) tremor. At a mean fol… Mon, 24 Apr 2017 04:00:00 GMT FDA Releases Non-Invasive VNS Therapy for Pain Associated with Episodic Cluster Headache The FDA has released the use of gammaCore, a non-invasive vagus nerve stimulator for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild electrical stimulation to the vagus nerve through the skin, resulting in a reduction of pain. The decision was based on subgroup analyses from two trials in the ACT (Non -- Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache) clinical trial program evaluating the safety … Tue, 18 Apr 2017 04:00:00 GMT Stroke Hospitalization Rates and Risk Factors Increasing in Young Adults Rates of acute ischemic stroke are increasing in young adults, new findings suggest (JAMA Neurology, April 10). Investigators analyzed stroke hospitalization rates as well as associated risk factors among patients between the ages of 18 and 64 years of age. They found that acute ischemic stroke hospitalization rates increased significantly for both men and women. Moreover, since 1995-1996, rates have almost doubled for men between 18 and 44 year of age, while rates for men and women aged 55 to 6… Mon, 17 Apr 2017 04:00:00 GMT First Treatment for Tardive Dyskinesia Approved in US The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of Ingrezza was shown in a clinical trial of 234 participants that compared Ingrezza to placebo. After six weeks, participants who received Ingrezza had improvement in the severity of abnormal involuntary movements compared to those who received placebo. Adverse events of Ingrezza include sleepiness a… Wed, 12 Apr 2017 04:00:00 GMT B. Smith and Husband Dan Gasby to Receive American Brain Foundation’s PLINA Award B. Smith and her husband Dan Gasby are the 2017 recipients of the American Brain Foundation’s Public Leadership in Neurology Award (PLINA). Smith is a celebrity chef, restaurateur, supermodel, and lifestyle maven, who was diagnosed with early-onset’s in 2013. Gasby recently joined the American Brain Foundation Board of Directors to help the Foundation make curing brain disease a high profile, public cause. The couple will receive the PLINA award during the Foundation’s Commitme… Thu, 6 Apr 2017 04:00:00 GMT New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for the disease. The approval was based on results from a phase 3 randomized, placebo-controlled study to assess the safety and efficacy of Austedo in reducing chorea in patients with HD (First-HD). In 90 ambulatory patients with manifest chorea associated with Huntington’s disease. Total Maximal Ch… Tue, 4 Apr 2017 04:00:00 GMT FDA Approves Expanded Indication For Qudexy XR Extended Release Capsules The FDA has approved two supplemental indications for Qudexy XR (topiramate, Upsher-Smith) Extended Release Capsules for use as prophylaxis of migraine headache in adults and adolescents 12 years of age and older. Qudexy XR capsules offer adolescents and adults with migraines a once-daily prophylactic medication that can be taken morning or night, with or without food. The capsules have also been approved for administration by opening and sprinkling the contents onto a small amount of soft food,… Thu, 30 Mar 2017 04:00:00 GMT Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that targets CD20 marker on B lymphocytes. It is the first drug approved in the US for the treatment of primary progressive MS. The approval was based on phase 3 results in both relapsing and primary progressive MS. In two identical studies evaluating ocrelizumab in relapsing MS known as the OPERA trials, the a… Tue, 28 Mar 2017 04:00:00 GMT New Evidence Suggests Potential for Blood-Based Alzheimer’s Biomarker Plasma neurofilament light (NFL) may represent a blood-based, non-invasive biomarker in Alzheimer’s disease (AD), according to new findings published in the JAMA Neurology (March 27, 2017). In a prospective case-control study, investigators used an ultrasensitive assay to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. In parti… Tue, 28 Mar 2017 04:00:00 GMT Review Identifies Antidepressants and AEDs Effective for Nerve Pain A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, researchers found moderate evidence in studies and systematic reviews that the antidepressants duloxetine and venlaxine, which act as serotonin-norepinephrine reuptake inhibitors, were effective in reducing neuropathy-related pain. They also found weak evidence that botulinum toxin, the anti-seizure drug… Fri, 24 Mar 2017 04:00:00 GMT Novel Adjunct Agent Approved for Parkinson’s "Off" Periods The FDA approved Xadago (safinamide, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. The approval is based on results from a clinical trial in which 645 patients receiving safinamide in addition to levodopa experienced more beneficial “on” time, when Parkinson’s symptoms are reduced. The increase in “on” time was accompanied by … Wed, 22 Mar 2017 04:00:00 GMT Sunovion Submits NDA to Expand Aptiom Indication to Pediatric Patients Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA to expand the indication for its antiepileptic drug AED Aptiom (eslicarbazepine acetate) to include use as monotherapy or adjunctive therapy for the treatment of partial-onset seizures (POS) in children four years of age and older. The submission is based on data from three clinical trials support the safety and tolerability of Aptiom for the treatment of POS in pediatric patients, along with pharmacokin… Tue, 14 Mar 2017 04:00:00 GMT ISC 2017: STRATIS Registry Re-Affirms Benefits of Mechanical Thrombectomy from Pivotal Acute Ischemic Stroke Trials Late-breaking results from the STRATIS (Systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke) registry re-affirm the benefits of mechanical thrombectomy that have been demonstrated in the four pivotal trials. STRATIS examined the impact of treatment delays on patient outcomes when treated with Medtronic’s Solitaire stent retriever and intravenous tissue plasminogen activator (IV-tPA), if eligible. Among 984 patients, 64 percent were treated wi… Thu, 23 Feb 2017 04:00:00 GMT ISC 2017: Integrative Aspiration System Compares Favorably to Stent Retrievers as Frontline Thrombectomy Therapy for Acute Stroke New research presented at the ongoing International Stroke Conference in Houston suggests that the ADAPT (A Direct Aspiration, First Pass Technique) compares favorably to the use of stent retrievers as an effective frontline thrombectomy approach. Data from the prospective, randomized controlled ASTER study showed that 85.4 percent of patients treated with Penumbra’s aspiration system achieved the primary endpoint of TICI 2b/3 at the end of the procedure, as compared to 83.1 percent of pat… Thu, 23 Feb 2017 04:00:00 GMT World’s Largest Seizure First Aid Training Set to Take Place in March On March 18, also known as “Purple Day,” the largest seizure first aid training in the world will be attempted at the Mall of America in Minneapolis, MN. The Guinness Book of World Records will be on hand to record the training session, which will take placing during the 3rd Annual Purple Day Walk for Epilepsy. All proceeds from the event will support the Anita Kaufmann Foundation’s mission to eliminate stigma and increase awareness of these conditions and their impact on famil… Thu, 23 Feb 2017 04:00:00 GMT ISC 2017: Exercise Significantly Improves Cognitive Impairment After Stroke New research presented at the ongoing International Stroke Conference 2017 suggests that structured exercise training can significantly improve brain function in stroke survivors. Given the prevalence of cognitive impairments after stroke, researchers evaluated the effects of different types of physical activity on cognitive function among stroke survivors. In their meta-analysis of 13 intervention trials, including a total of 735 participants, the investigators found that structured physical ac… Thu, 23 Feb 2017 04:00:00 GMT FDA Accepts NDA Filing for MT Pharma’s Investigational ALS Treatment The FDA accepted the Mitsubishi Tanabe Pharma’s New Drug Application (NDA) for edaravone (MCI-186), an intravenous treatment for amyotrophic lateral sclerosis (ALS). Edaravone is described as a free radical scavenger that is believed to relieve the effects of oxidative stress, a likely factor in the onset and progression of ALS. The NDA is supposed by a clinical research program in patients diagnosed with ALS in Japan. In 2015, edaravone was approved for use as a treatment for ALS in Japan… Fri, 17 Feb 2017 04:00:00 GMT Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease experiencing OFF periods. The SPAN-PD trial randomized 339 people with Parkinson's disease who experience motor fluctuations to receive one of two doses of CVT-301 or placebo. All participants were on a stable regimen of oral carbidopa and levodopa, and were also maintained on their other existing Pa… Fri, 10 Feb 2017 04:00:00 GMT New Corticosteroid Approved for Duchenne Muscular Dystrophy The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA approved corticosteroid to treat DMD and the first approval of deflazacort for any use in the US. In a clinical study of 196 male patients between the ages of five and 15 years with documented mutations of the dystrophin gene and onset of weakness at age five, patients taking deflazacort had improvements in clinical assessm… Fri, 10 Feb 2017 04:00:00 GMT Blood Biomarker for Quick and Accurate Prognosis of MS Identified A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports, investigators evaluated the links between inflammation, the kynurenine pathway (KP), and multiple sclerosis. They found that abnormalities in the KP appear to be associated with the switch from early-mild stage MS to debilitating progressive forms of MS. They also learned that serum KP metabolic signatures in patients can… Tue, 7 Feb 2017 04:00:00 GMT Burnout Affects 60 Percent of US Neurologists More than half of practicing neurologists in the US are experiencing some form of burnout, according to a new study published online in Neurology (January 25). The study involved 1,671 neurologists with a median age of 51 years and an average 17 years in practice. Participants reported working an average of 56 hours per week, with three-fourths of that time spent in clinical care. One-third of neurologists worked in academic practice, or a university setting, and the rest in clinical practic… Thu, 26 Jan 2017 04:00:00 GMT